Search Results

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

Wuke Superconducting Completes Tens of Millions in Angel Round Financing, Accelerating the Industrialization of High-Temperature Superconducting Tapes

In late July 2026, Beijing Wuke Superconducting Technology Co., Ltd. (hereinafter referred to as "Wuke Superconducting") completed an angel round financing of tens of millions of RMB. This round was jointly invested by CASSTAR, Zhongguancun Capital, and Huairou Hard Technology Fund. The joint backing of several renowned venture capital institutions fully confirms the capital market's high recognition of Wuke Superconducting's core team, technical strength, and industry development prospects. Wuke Superconducting was initiated by the technical team of the Institute of Physics, Chinese Academy of Sciences, focusing on the R&D, preparation, and industrial application of a new generation of high-temperature superconducting tapes. The company is dedicated to overcoming the key bottlenecks in transitioning high-temperature superconducting materials from laboratory to large-scale application, building an integrated platform covering superconducting target development, core equipment R&D, high-performance tape preparation, and ultimate performance characterization of wires and tapes.

2026-08-03

Guomai Fusion Energy Completes Angel+ Round Financing, with Zhengxuan Investment and Others Supporting aFRC Fusion Route Commercialization

Recently, Beijing Guomai Fusion Energy Technology Co., Ltd. (hereinafter referred to as Guomai Fusion Energy) completed its Angel+ round of financing. This round was participated by well-known institutions such as Zhengxuan Investment and Dalin Investment. By adopting a strategy of small steps and rapid iteration, Guomai Fusion Energy has continuously advanced its financing, pooling industrial and capital forces to support R&D design and engineering validation, and promoting the fast and sound development of the advanced field-reversed configuration (aFRC) route. The funds from this round will be primarily used for aFRC route R&D, including the construction of fusion experimental devices, core technology breakthroughs, and talent team building, accelerating key technology breakthroughs and experimental validation. Guomai Fusion Energy, established in the Beijing Economic-Technological Development Area, is a company focusing on advanced field-reversed config...

2026-07-31

U.S. Fusion Energy Company CFS Completes $1 Billion Equity Financing

U.S. fusion energy startup Commonwealth Fusion Systems (CFS) announced on July 30 that it has completed $1 billion in new equity financing. The company stated that this is one of the largest single-round financings globally for a fusion energy company since its $1.8 billion Series B round in 2021. To date, CFS has raised a total of $4 billion, accounting for nearly 30% of the cumulative global fusion industry financing. Headquartered in Devens, Massachusetts, CFS was founded in 2018. The company is primarily advancing the SPARC fusion demonstration device and the ARC commercial fusion power plant project. Fusion reactions release energy by combining light atoms such as hydrogen under extremely high temperatures and pressures, and are considered a potential low-carbon energy pathway. However, fusion reactors are still in the experimental and engineering validation stage, with related technologies facing challenges such as material resistance to neutron bombardment and improving reaction efficiency.

2026-07-30